Notably, TP53 mutations with high VAFs in HCC are frequently linked to impaired p53 signaling, contributing to therapeutic resistance, increased tumor aggressiveness, and defective apoptotic responses (Vokes et al., 2022). The gene discussed is TP53; the disease is neoplasm.